132945-76-7

Basic information

• Product Name: (R)-1-Boc-3-cyanopyrrolidine
• Synonyms: (R)-1-Boc-3-cyanopyrrolidine;(R)-1-Boc-3-cyanopyrrolid...;tert-butyl (3R)-3-cyanopyrrolidine-1-carboxylate;(R)-N-Boc-Cyanopyrrolidine;(R)-1-N-Boc-3-Cyano-pyrrolidine(R)-1-N-Boc-3-Cyano-pyrrolidine
• CAS NO: 132945-76-7
• Molecular Formula: C₁₀H₁₆N₂O₂
• Molecular Weight: 196.25
• Product Categories: Pyrrole&Pyrrolidine&Pyrroline
• Mol File: 132945-76-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 307.9 °C at 760 mmHg
• Flash Point: 140 °C
• Appearance: /
• Density: 1.08 g/cm³
• Vapor Pressure: 0.000703mmHg at 25°C
• Refractive Index: 1.488
• Storage Temp.: 2-8°C
• PKA: -3.73±0.40(Predicted)
• BRN: 8683216
• CAS DataBase Reference: (R)-1-Boc-3-cyanopyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-Boc-3-cyanopyrrolidine(132945-76-7)
• EPA Substance Registry System: (R)-1-Boc-3-cyanopyrrolidine(132945-76-7)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 132945-76-7(Hazardous Substances Data)

Usage

Description

(R)-1-Boc-3-cyanopyrrolidine is a chiral compound featuring a pyrrolidine ring with a Boc-protecting group and a cyano substituent at the 3-position. It is an important building block in organic synthesis, particularly in the preparation of pharmaceuticals and biologically active molecules.

Uses

Used in Pharmaceutical Synthesis:
(R)-1-Boc-3-cyanopyrrolidine is used as a key intermediate in the synthesis of β-proline analogs, such as (3R)-carboxy pyrrolidine. These analogs are valuable in the development of novel drugs with improved pharmacological properties and selectivity.
Used in Antimicrobial Agents:
(R)-1-Boc-3-cyanopyrrolidine is used in the preparation of 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid compounds, which exhibit anti-microbial properties. These compounds can be employed as potential therapeutic agents against various microbial infections, contributing to the development of new antibiotics and antimicrobial drugs.

InChI:InChI=1/C10H16N2O2/c1-10(2,3)14-9(13)12-5-4-8(6-11)7-12/h8H,4-5,7H2,1-3H3/t8-/m0/s1

Upstream product

• 2408-36-8 lithium cyanide 
• 132945-75-6 (S)-tert-butyl 3-(methylsulfonyloxy)pyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 143-33-9 sodium cyanide 
• 773837-37-9 sodium cyanide 

Downstream Products

• 471254-10-1 (3R)-pyrrolidine-3-carboxamide 
• 199174-29-3 tert-butyl (R)-3-(aminomethyl)pyrrolidine-1-carboxylate 
• 199175-10-5 1,1-dimethylethyl (3S)-3-(aminomethyl)-1-pyrrolidinecarboxylate 
• 1366767-72-7 1,1-dimethylethyl (3R)-3-{[5-(4-bromophenyl)-1H-tetrazol-1-yl]methyl}-1-pyrrolidinecarboxylate 
• 1366767-74-9 5-(4-bromophenyl)-1-{[(3R)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-1H-tetrazole 

Relevant articles and documents

FATTY ACID SYNTHASE INHIBITORS

This invention relates to carboxamides and reverse carboxamides according to Formula (I) and the use of carboxamides and reverse carboxamides for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of carboxamides and reverse carboxamides in the treatment of cancer.

BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of benzimidazoles in the treatment of cancer.

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.